Table 1.
Baseline serostatus and seroconversion following live oral adenovirus-4 and 7 vaccination 30 days to 1 year.
| Vaccination and Immune Status | Adenovirus-4 | Adenovirus-7 | ||
|---|---|---|---|---|
| Seronegative (% or CI) | Seropositive (% or CI) | Seronegative (% or CI) | Seropositive (% or CI) | |
| Baseline serostatus | 18 (30%) | 42 (70%) | 18 (30%) | 42 (70%) |
| Seroconversion/4-fold increase * | 18 (100%) | 18 (43%) | 16 (89%) | 25 (60%) |
| Pre-vaccination GMT | <4 | 8 (5–13) | <4 | 16 (10–26) |
| <30–1 year GMT | 26 (17–39) | 110 (76–161) | 69 (38–126) | 120 (87–165) |
* Determined as a detectable 50% neutralizing antibody titers (NT50) ≥ 4 for seronegative subjects or a 4-fold increased from baseline NT50 compared to NT50 at <30 days–1 year for seropositive subjects. GMT = geometric mean titer and only determine for subjects with vaccine specific antibody response. CI = lower and upper 95% confidence interval for GMT.